[Alzheimer's Drug Discovery Foundation](https://www.alzdiscovery.org)

November 9, 2018 (Letter of Intent) | February 15, 2019 (Invited Full Proposal) | June 1, 2026 (Full Proposal)

Up to $2,500,000 over 1–3 years; typical awards range from $500,000–$2,000,000.

Supports early-stage clinical trials of drugs or devices for frontotemporal degeneration (FTD), advancing understanding, biomarkers, and therapies.

--- ## Description The Treat FTD Fund is a joint initiative of the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD), designed to accelerate the development of novel or repurposed therapeutics and devices for frontotemporal degeneration (FTD) disorders. The fund addresses the unique challenges of FTD drug development by supporting early/mid-stage clinical trials, trial readiness activities, and projects with strong scientific rationale and clear hypotheses. Emphasis is placed on innovative trial designs, patient-relevant outcomes, the use of informative biomarkers, and data sharing to advance the field. Both disease-modifying and symptomatic interventions are eligible, with a focus on approaches applicable to both genetic and sporadic forms of FTD. --- ## Due Dates - November 9, 2018: Letter of Intent deadline - February 15, 2019: Invited Full Proposal deadline - June 1, 2026: Full Proposal deadline --- ## Funding Amount - Awards range from $500,000 to $2,000,000, with a maximum of $2,500,000 over 1–3 years, depending on the stage and scope of the trial. - Payment structure is milestone-based and may be negotiated according to patient enrollment and project progress. - Co-funding from other agencies or investors is encouraged for larger studies. --- ## Eligibility - Open to researchers and clinicians worldwide. - Eligible institutions include: - Academic medical centers, universities, and non-profit organizations (industry partnerships encouraged). - Biotechnology companies (existing or new spinouts) that demonstrate a need for non-profit funding; funding is provided through mission-related investments requiring return on investment based on milestones. - Projects must focus on clinical trials (phase 0, 1, or 2) for FTD disorders, including prevention trials in at-risk individuals. - Both drug and device interventions are eligible; non-pharmacologic/lifestyle interventions are not considered. --- ## Application Process - **Step 1: Letter of Intent (LOI)** - Submit via the [ADDF Funding Portal](https://addf.fluxx.io/). - Includes project details, novelty/rationale, disease target, drug/device description, clinical trial design, and key supporting data. - **Step 2: Invited Full Proposal** - Only invited applicants may submit a full proposal. - Full proposals must include an executive lay summary, biographical summaries, project narrative (background, supporting data, plan, design, team, IP, research support, references), and relevant forms (compound report card, human subjects questionnaire, budget). - Biotechnology companies must submit a business packet (business plan, management structure, financial statements, IP summary, etc.). - Optional supplemental materials may include IRB-ready protocols, vendor quotes, letters of support, and unpublished manuscripts. - **Review Process** - LOIs are screened for alignment with fund priorities. - Full proposals are reviewed by scientific and business review boards. - Applicants may receive feedback or requests for revisions. - **Registration** - Applicants must register for the ADDF Funding Portal; allow 1–2 business days for approval. --- ## Additional Information - Clinical trials should include clear go/no-go milestones and utilize patient-relevant outcomes and informative biomarkers. - Projects must have a plan for data sharing. - For device-based interventions, applicants are encouraged to contact the fund before applying. - Studies in both genetic and sporadic forms of FTD are welcome, with a particular emphasis on approaches for sporadic FTD. --- ## External Links - [Treat FTD Fund Program Page](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/the-treat-ftd-fund) - [Application Instructions](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/the-treat-ftd-fund/the-treat-ftd-fund-application-instructions) - [ADDF Funding Portal](https://addf.fluxx.io/) - [Application and Funding Policies](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/policies) - [Outcome Measures Recommendations for Early-Stage Trials](https://pubmed.ncbi.nlm.nih.gov/33674360/) --- ## Contact Information | Purpose | Contact Name/Team | Email Address | |------------------------------------|------------------------------------------|------------------------------------------------| | Program-related inquiries (ADDF) | Aaron Burstein, PharmD | [aburstein@alzdiscovery.org](mailto:aburstein@alzdiscovery.org?subject=AFTD%20RFP) | | Program-related inquiries (AFTD) | Nicole Bjorklund, PhD | [nbjorklund@theaftd.org](mailto:nbjorklund@theaftd.org?subject=Treat%20FTD%20RFP) | | Application submission inquiries | Grants and Mission-Related Investments | [grants@alzdiscovery.org](mailto:grants@alzdiscovery.org?subject=FTD%20RFP) | | General foundation contact | Alzheimer's Drug Discovery Foundation | [info@alzdiscovery.org](mailto:info@alzdiscovery.org) / 212.901.8000 | | Foundation contact page | | [Contact Form](https://www.alzdiscovery.org/contact-us) |

Treat FTD Fund

Sign in to see full grant listing